Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Clinical Therapeutics
|
September 21, 2002
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review
Paul Emery, Sheldon X Kong, Elliot W Ehrich, et al.
Molecular Psychiatry
|
June 30, 2018
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Marta Peciña, Jordan F Karp, Sanjay Mathew, et al.
The Journal of Rheumatology
|
November 28, 2000
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis
E W Ehrich, G M Davies, D J Watson, et al.
Alcoholism, Clinical and Experimental Research
|
February 28, 2006
Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone
Joi L Dunbar, Ryan Z Turncliff, Qunming Dong, et al.
The Journal of Experimental Medicine
|
August 1, 1993
T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen
E W Ehrich, B Devaux, E P Rock, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
February 1, 1996
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
C Brideau, S Kargman, S Liu, et al.
International Clinical Psychopharmacology
|
October 31, 2015
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia
Leslie Citrome, Yangchun Du, Robert Risinger, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
The International Journal of Eating Disorders
|
February 6, 2013
A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder
Susan L McElroy, Anna I Guerdjikova, Thomas J Blom, et al.
Journal of Clinical Pharmacology
|
October 22, 2005
Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
Ryan Z Turncliff, Joi L Dunbar, Qunming Dong, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Clinical Therapeutics
|
September 21, 2002
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review
Paul Emery, Sheldon X Kong, Elliot W Ehrich, et al.
Molecular Psychiatry
|
June 30, 2018
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Marta Peciña, Jordan F Karp, Sanjay Mathew, et al.
The Journal of Rheumatology
|
November 28, 2000
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis
E W Ehrich, G M Davies, D J Watson, et al.
Alcoholism, Clinical and Experimental Research
|
February 28, 2006
Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone
Joi L Dunbar, Ryan Z Turncliff, Qunming Dong, et al.
The Journal of Experimental Medicine
|
August 1, 1993
T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen
E W Ehrich, B Devaux, E P Rock, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
February 1, 1996
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
C Brideau, S Kargman, S Liu, et al.
International Clinical Psychopharmacology
|
October 31, 2015
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia
Leslie Citrome, Yangchun Du, Robert Risinger, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
The International Journal of Eating Disorders
|
February 6, 2013
A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder
Susan L McElroy, Anna I Guerdjikova, Thomas J Blom, et al.
Journal of Clinical Pharmacology
|
October 22, 2005
Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
Ryan Z Turncliff, Joi L Dunbar, Qunming Dong, et al.
Page
of 4